

m. (1R)-N-Methyl-2 $\beta$ -Methoxycarbonyl-3 $\alpha$ -(3,4-dichlorophenyl)-8-aza-bicyclo[3.2.1]octane;

n. (1R)-N-Methyl-2 $\beta$ -Methoxycarbonyl-3 $\alpha$ -(4-fluorophenyl)-8-azabicyclo[3.2.1]octane;

o. (1R)-N-Methyl-2 $\beta$ -methoxycarbonyl-3 $\alpha$ -(2-naphthyl)-8-azabicyclo[3.2.1]octane;

p. (1R)-2 $\beta$ -Methoxycarbonyl-3 $\alpha$ -(2-naphthyl)-8-azabicyclo[3.2.1]octane.--

REMARKS


It is respectfully submitted that the present application is in condition for allowance.

Should the Examiner wish to discuss the above amendment made herein, the undersigned attorney would appreciate the opportunity to do so. Thus the Examiner is hereby invited to call the undersigned, collect at the number shown below.

Respectfully submitted,

Date: Oct. 11, 2001

BOS2\_179946.1

  
Cara Z. Lowen (Reg. No.: 38,227)  
Dike, Bronstein, Roberts & Cushman  
Intellectual Property Practice Group of  
EDWARDS & ANGELL, LLP  
P.O. Box 9169  
Boston, MA 02209  
(617) 439-4444